2. Search Result
Search Result
Results for "

GAB

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS05197
    GAB1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    GAB1 Human Pre-designed siRNA Set A contains three designed siRNAs for GAB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    GAB1 Human Pre-designed siRNA Set A
    GAB1 Human Pre-designed siRNA Set A
  • HY-RS05198
    GAB2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    GAB2 Human Pre-designed siRNA Set A contains three designed siRNAs for GAB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    GAB2 Human Pre-designed siRNA Set A
    GAB2 Human Pre-designed siRNA Set A
  • HY-RS05199
    GAB3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    GAB3 Human Pre-designed siRNA Set A contains three designed siRNAs for GAB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    GAB3 Human Pre-designed siRNA Set A
    GAB3 Human Pre-designed siRNA Set A
  • HY-RS05200
    GAB4 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    GAB4 Human Pre-designed siRNA Set A contains three designed siRNAs for GAB4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    GAB4 Human Pre-designed siRNA Set A
    GAB4 Human Pre-designed siRNA Set A
  • HY-135034
    UMB68 sodium

    		GABA Receptor Neurological Disease
    UMB68 sodium is a selective GHB receptor ligand. UMB68 sodium displaces [ 3H]NCS-382 with an IC50 of 38 nM in rat cerebrocortical membranes. UMB68 sodium has no significant affinity at GABAB receptors, cannot be metabolized to GABA-active compounds .
    UMB68 sodium
  • HY-13404
    Capmatinib
    Maximum Cited Publications
    8 Publications Verification

    INC280; INCB28060

    		 c-Met/HGFR Apoptosis Cancer
    Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .
    Capmatinib
  • HY-13404B
    Capmatinib hydrochloride

    INC280 hydrochloride; INCB-28060 hydrochloride

    		 c-Met/HGFR Apoptosis Cancer
    Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
    Capmatinib hydrochloride
  • HY-13404C
    Capmatinib dihydrochloride hydrate
    Maximum Cited Publications
    8 Publications Verification

    INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate

    		 c-Met/HGFR Apoptosis Cancer
    Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .
    Capmatinib dihydrochloride hydrate
  • HY-13404A
    Capmatinib dihydrochloride

    INC280 dihydrochloride; INCB28060 dihydrochloride

    		 c-Met/HGFR Apoptosis Cancer
    Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
    Capmatinib dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: